论文部分内容阅读
目的对比泮托拉唑与雷贝拉唑治疗幽门螺杆菌(Hp)感染活动性胃溃疡成本—效果分析。方法抽取医院2015年11月-2016年11月收治的Hp感染活动期胃溃疡患者89例作为研究对象,随机分为泮托拉唑组(45例)和雷贝拉唑组(44例),比较2组患者的临床效果及花费成本。结果总有效率泮托拉唑组为97.78%,雷贝拉唑组为97.73%,2组比较差异无统计学意义(P>0.05);泮托拉唑组花费成本显著低于雷贝拉唑组,差异有统计学意义(P<0.05)。结论泮托拉唑和雷贝拉唑作为经典质子泵抑制剂治疗Hp感染活动性胃溃疡效果显著,但泮托拉唑更具药物经济学价值。
Objective To compare the cost-effectiveness of pantoprazole and rabeprazole in the treatment of active gastric ulcer infected with Helicobacter pylori (Hp). Methods Eighty-nine patients with Hp-infected gastric ulcer admitted from November 2015 to November 2016 in our hospital were randomly divided into the pantoprazole group (n = 45) and the rabeprazole group (n = 44) The clinical effect and cost of the two groups were compared. Results The total effective rate was 97.78% in the pantoprazole group and 97.73% in the rabeprazole group. There was no significant difference between the two groups (P> 0.05). The cost of pantoprazole group was significantly lower than that of rabeprazole Group, the difference was statistically significant (P <0.05). Conclusions Pantoprazole and rabeprazole are effective as classical proton pump inhibitors in treating Hp infection in patients with active gastric ulcer, but pantoprazole has more pharmacological and economic value.